| 摘要 |
The present invention relates to MDA-7 variant proteins which are deficient in or lack glycosylation. It is based, at least in part, on the results of experiments which have demonstrated that such variants are functionally equivalent to wild-type MDA-7 protein. Such proteins may be more easily produced large-scale than the wild-type protein, and may be found to be less immunogenic (thereby facilitating treatment, especially repeated treatments). Accordingly, the present invention provides for such proteins (‘Gly(def)MDA-7 proteins’), nucleic acids encoding them (‘Gly(def)mda-7 nucleic acids), pharmaceutical compositions comprising such proteins or nucleic acids, and related methods of treatment.
|
